Form4insider filings, from the source

SEC Form 3 · accession 0002141655-26-000006

Attovia Therapeutics, Inc. · ATTO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Petter Veiby
Officer — Chief Scientific Officer
Period of report
Aug 4, 2026
Accepted (ET)
Aug 4, 2026 · 7:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0002058707

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———104,951D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F1$2.8799holding————Mar 5, 2034Common Stock5,382—D
Stock Option (Right to Buy)F2$3.5302holding————May 8, 2034Common Stock107,642—D
Stock Option (Right to Buy)F3$4.9237holding————May 17, 2035Common Stock89,343—D
Stock Option (Right to Buy)F4$1.5793holding————Aug 16, 2033Common Stock18,837—D

Explanation of responses